SCHEMBL4932865

SCHEMBL4932865

COc1cc(O)c(-c2noc3ccccc23)cc1CNc1ccc(C)c(C)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.50
ALDH1A1 P00352 5/20 0.44
GAA P10253 4/20 0.44
TDP1 Q9NUW8 4/20 0.44
L3MBTL1 Q9Y468 4/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
KMT2A Q03164 5/20 0.43
KDM4E B2RXH2 4/20 0.43
MEN1 O00255 4/20 0.43
NPC1 O15118 2/20 0.43
LMNA P02545 2/20 0.43
ALOX15 P16050 2/20 0.43
HTT P42858 2/20 0.43
MAPK1 P28482 2/20 0.43
TSHR P16473 1/20 0.43
GFER P55789 1/20 0.43
ESR1 P03372 2/20 0.41
ESR2 Q92731 2/20 0.41
TUBB4A P04350 1/20 0.40
TUBB P07437 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4928663 0.93 MAPT (0.45) MAPTALDH1A1GAATDP1L3MBTL1
SCHEMBL4928618 0.89 MAPT (0.54) MAPTALDH1A1GAATDP1L3MBTL1
SCHEMBL4935041 0.86 MAPT (0.51) MAPTALDH1A1GAATDP1L3MBTL1
SCHEMBL4933048 0.81 HIF1A (0.41) MAPTALDH1A1GAASMN1; SMN2KMT2A
SCHEMBL4934925 0.80 MAPT (0.41) MAPTALDH1A1GAATDP1L3MBTL1
SCHEMBL4928567 0.75 ESR1 (0.50) MAPTALDH1A1GAATDP1L3MBTL1
SCHEMBL4932010 0.74 MAPT (0.48) MAPTGAAL3MBTL1SMN1; SMN2KMT2A
SCHEMBL4931003 0.71 ESR1 (0.44) MAPTALDH1A1SMN1; SMN2KMT2AKDM4E
SCHEMBL2767665 0.70 EPHX2 (0.48) MAPTALDH1A1GAATDP1L3MBTL1
SCHEMBL5713675 0.69 TUBB4A (0.63) MAPTALDH1A1GAATDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080070960-A1 Novel 3-Aryl-1,2-Benzisoxazole Derivatives and Use Thereof as Medicinal Products Against Cancer AVENTIS PHARMA S.A. (FR) 2008-03-20 US disclosed
US-20080070960-A1 Novel 3-Aryl-1,2-Benzisoxazole Derivatives and Use Thereof as Medicinal Products Against Cancer AVENTIS PHARMA S.A. (FR) 2008-03-20 US disclosed
US-20080070960-A1 Novel 3-Aryl-1,2-Benzisoxazole Derivatives and Use Thereof as Medicinal Products Against Cancer AVENTIS PHARMA S.A. (FR) 2008-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070960-A1 Novel 3-Aryl-1,2-Benzisoxazole Derivatives and Use Thereof as Medicinal Products Against Cancer UGT2B7, UGT2B17, CYP4X1 MAPT 4708/4885ALDH1A1 39/4885GAA 331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.